UY27816A1 - NEW COMBINATION - Google Patents

NEW COMBINATION

Info

Publication number
UY27816A1
UY27816A1 UY27816A UY27816A UY27816A1 UY 27816 A1 UY27816 A1 UY 27816A1 UY 27816 A UY27816 A UY 27816A UY 27816 A UY27816 A UY 27816A UY 27816 A1 UY27816 A1 UY 27816A1
Authority
UY
Uruguay
Prior art keywords
new combination
inhibitor
pde5
cgmp
ace
Prior art date
Application number
UY27816A
Other languages
Spanish (es)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY27816A1 publication Critical patent/UY27816A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las combinaciones que comprenden a) un inhibidor de fosfodiesterasa de tipo 5 (PDE5) específica de monofosfato de guanosina c´clico (GMPc) y b) un inhibidor de enzima de conversión de angiotensina (ACE) son útiles para tratar la hipertensión.Combinations comprising a) a cyclic guanosine monophosphate type 5 (PDE5) phosphodiesterase inhibitor (cGMP) and b) an angiotensin conversion enzyme (ACE) inhibitor are useful for treating hypertension.

UY27816A 2002-05-23 2003-05-21 NEW COMBINATION UY27816A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
UY27816A1 true UY27816A1 (en) 2003-12-31

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27816A UY27816A1 (en) 2002-05-23 2003-05-21 NEW COMBINATION

Country Status (18)

Country Link
EP (1) EP1506015A2 (en)
JP (1) JP2005529927A (en)
KR (1) KR20050004195A (en)
CN (1) CN1655820A (en)
AR (1) AR040090A1 (en)
AU (1) AU2003223071A1 (en)
BR (1) BR0311191A (en)
CA (1) CA2485984A1 (en)
IL (1) IL164975A0 (en)
MX (1) MXPA04010951A (en)
NO (1) NO20045517L (en)
PA (1) PA8574201A1 (en)
PE (1) PE20040514A1 (en)
PL (1) PL374198A1 (en)
RU (1) RU2004133973A (en)
TW (1) TW200407153A (en)
UY (1) UY27816A1 (en)
WO (1) WO2003099194A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (en) * 2006-06-13 2012-12-07 Bioprojet Soc Civ USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
BRPI0716571A2 (en) * 2006-08-24 2013-11-05 Surface Logix Inc PHARMACEUTICALLY OPTIMIZED COMPOUNDS
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN105377235A (en) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA3176466A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB2346877B (en) * 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TR200200954T2 (en) * 1999-10-11 2002-09-23 Pfizer Inc. As phosphodiesterase inhibitors 5- (2-substituted-5-heterocyclylsulfonylpyrid-3-yl) - dihydropyrazolo [4,3-D] pyrimidine-7-they.
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
TW200407153A (en) 2004-05-16
BR0311191A (en) 2005-03-01
NO20045517L (en) 2004-12-17
CN1655820A (en) 2005-08-17
JP2005529927A (en) 2005-10-06
WO2003099194A2 (en) 2003-12-04
PL374198A1 (en) 2005-10-03
MXPA04010951A (en) 2005-06-08
KR20050004195A (en) 2005-01-12
CA2485984A1 (en) 2003-12-04
AU2003223071A1 (en) 2003-12-12
PE20040514A1 (en) 2004-08-24
RU2004133973A (en) 2005-09-10
WO2003099194A3 (en) 2004-06-03
EP1506015A2 (en) 2005-02-16
PA8574201A1 (en) 2003-12-19
IL164975A0 (en) 2005-12-18
AR040090A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1105390T1 (en) THERAPEUTIC MANAGEMENT OF PULMONARY HYPERTENSION
UY27816A1 (en) NEW COMBINATION
ECSP056173A (en) COMPOSITION THAT INCLUDES A PDE4 INHIBITOR AND A PDE5 INHIBITOR
ECSP034519A (en) XANTINA PHOSPHODIESTERASE V INHIBITORS
DK1073658T3 (en) Pyrazolopyrimidinone cGMP PDE5 Inhibitors for the Treatment of Sexual Disorder
DK1440709T3 (en) Combinations comprising cGMP PDE5 inhibitors
IS6689A (en) Phosphonate-nucleotide analogues and methods used to select and create them
NO20050400L (en) New combination preparation
DE60323417D1 (en) Gas turbine combustion chamber
NO20001583D0 (en) Stimulation of hematopoietic cells in vitro
DK1268480T3 (en) 8-Quinoline xanthine and 8-isoquinoline xanthine derivatives as PDE5 inhibitors
DE60134692D1 (en) Lighting arrangement for keyboards and the dynamic or individual illumination of the keys and methods for their use
UY27729A1 (en) QUINASE INHIBITORS.
HN2003000285A (en) NEW ESPIROCONDENSED QUINAZOLINONES AND ITS USE AS PHOSPHODIESTERASE INHIBITORS
ATE234091T1 (en) THROMBIN INHIBITORS
BR0314196A (en) Tgf-beta inhibitors
GT200300231A (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
MXPA05006368A (en) Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2.
AR030718A1 (en) BACILLUS THURINGIENSIS PROTEINS INHIBITING INSULTS FUSIONS AND METHODS OF USE OF THE SAME
DK1285065T3 (en) Constructed proteins that fluoresce at long wavelengths
DOP2003000645A (en) NEW COMBINATION
GB0000561D0 (en) Treatment of diabetic ulcers
PA8477601A1 (en) FKBP INHIBITORS
DE60136573D1 (en) GEWEBEFIXATIVZUSAMMENSETZUNG
DOP2003000649A (en) NEW COMBINATION

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520